Meiji Yasuda Life Insurance Co lessened its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 8.8% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 28,474 shares of the company's stock after selling 2,758 shares during the period. Eli Lilly and Company comprises 0.4% of Meiji Yasuda Life Insurance Co's investment portfolio, making the stock its 21st biggest holding. Meiji Yasuda Life Insurance Co's holdings in Eli Lilly and Company were worth $21,982,000 at the end of the most recent reporting period.
A number of other large investors also recently modified their holdings of LLY. Highline Wealth Partners LLC grew its holdings in shares of Eli Lilly and Company by 80.0% during the fourth quarter. Highline Wealth Partners LLC now owns 45 shares of the company's stock worth $35,000 after buying an additional 20 shares during the last quarter. FPC Investment Advisory Inc. grew its stake in shares of Eli Lilly and Company by 358.3% in the 4th quarter. FPC Investment Advisory Inc. now owns 55 shares of the company's stock valued at $45,000 after purchasing an additional 43 shares during the last quarter. Prudent Man Investment Management Inc. acquired a new position in shares of Eli Lilly and Company in the fourth quarter valued at approximately $48,000. Compass Financial Services Inc purchased a new stake in shares of Eli Lilly and Company during the fourth quarter worth approximately $50,000. Finally, Fiduciary Advisors Inc. acquired a new stake in shares of Eli Lilly and Company during the fourth quarter worth $58,000. 82.53% of the stock is owned by hedge funds and other institutional investors.
Eli Lilly and Company Stock Performance
Shares of NYSE:LLY traded up $31.00 during trading on Friday, hitting $825.10. 6,056,616 shares of the company traded hands, compared to its average volume of 3,477,597. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00. The business's fifty day moving average is $825.36 and its 200-day moving average is $815.67. The stock has a market capitalization of $782.34 billion, a price-to-earnings ratio of 70.46, a PEG ratio of 1.40 and a beta of 0.51. Eli Lilly and Company has a one year low of $677.09 and a one year high of $972.53.
Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). The company had revenue of $12.73 billion for the quarter, compared to the consensus estimate of $12.77 billion. Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. Eli Lilly and Company's quarterly revenue was up 45.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.58 earnings per share. As a group, equities analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Several research analysts recently issued reports on the stock. Leerink Partners set a $950.00 price target on shares of Eli Lilly and Company in a report on Friday, January 17th. Cantor Fitzgerald started coverage on Eli Lilly and Company in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $975.00 price target for the company. UBS Group dropped their price objective on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating on the stock in a report on Friday. Morgan Stanley reaffirmed an "overweight" rating on shares of Eli Lilly and Company in a research note on Thursday. Finally, Guggenheim reiterated a "buy" rating on shares of Eli Lilly and Company in a research note on Thursday. One analyst has rated the stock with a sell rating, two have given a hold rating and nineteen have assigned a buy rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $1,002.80.
Check Out Our Latest Stock Report on LLY
Insider Buying and Selling at Eli Lilly and Company
In other news, CAO Donald A. Zakrowski sold 1,000 shares of Eli Lilly and Company stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the sale, the chief accounting officer now owns 5,840 shares of the company's stock, valued at approximately $4,778,521.60. The trade was a 14.62 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 0.13% of the stock is currently owned by company insiders.
About Eli Lilly and Company
(
Free Report)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Read More
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
